JP2014531584A5 - - Google Patents

Download PDF

Info

Publication number
JP2014531584A5
JP2014531584A5 JP2014530245A JP2014530245A JP2014531584A5 JP 2014531584 A5 JP2014531584 A5 JP 2014531584A5 JP 2014530245 A JP2014530245 A JP 2014530245A JP 2014530245 A JP2014530245 A JP 2014530245A JP 2014531584 A5 JP2014531584 A5 JP 2014531584A5
Authority
JP
Japan
Prior art keywords
cells
ccr9
foxp3
amount
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014530245A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014531584A (ja
JP6389122B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/068146 external-priority patent/WO2013037970A1/en
Publication of JP2014531584A publication Critical patent/JP2014531584A/ja
Publication of JP2014531584A5 publication Critical patent/JP2014531584A5/ja
Application granted granted Critical
Publication of JP6389122B2 publication Critical patent/JP6389122B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014530245A 2011-09-15 2012-09-14 抗ｓｍａｄ７治療に対する応答性をモニターするための方法 Expired - Fee Related JP6389122B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11425234 2011-09-15
EP11425234.9 2011-09-15
US201161576556P 2011-12-16 2011-12-16
US61/576,556 2011-12-16
PCT/EP2012/068146 WO2013037970A1 (en) 2011-09-15 2012-09-14 Methods for monitoring responsiveness to anti-smad7 therapy

Publications (3)

Publication Number Publication Date
JP2014531584A JP2014531584A (ja) 2014-11-27
JP2014531584A5 true JP2014531584A5 (https=) 2015-11-05
JP6389122B2 JP6389122B2 (ja) 2018-09-12

Family

ID=47882658

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014530245A Expired - Fee Related JP6389122B2 (ja) 2011-09-15 2012-09-14 抗ｓｍａｄ７治療に対する応答性をモニターするための方法

Country Status (11)

Country Link
US (2) US9791442B2 (https=)
EP (2) EP3165929A3 (https=)
JP (1) JP6389122B2 (https=)
KR (1) KR102099990B1 (https=)
CN (1) CN104040349B (https=)
AU (1) AU2012307336B2 (https=)
CA (1) CA2848595A1 (https=)
ES (1) ES2617200T3 (https=)
MX (1) MX350087B (https=)
RU (1) RU2678450C2 (https=)
WO (1) WO2013037970A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
RU2593939C2 (ru) 2008-11-13 2016-08-10 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
AU2014229985B2 (en) * 2013-03-15 2018-12-13 Nogra Pharma Limited Methods of treating colorectal cancer
US20160139123A1 (en) * 2013-07-12 2016-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Shear Wave Imaging Method and Installation for Collecting Information on a Soft Solid
AU2015257589A1 (en) * 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3213070A2 (en) * 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
EP3329276A2 (en) * 2015-07-27 2018-06-06 H. Hoffnabb-La Roche Ag Methods for diagnosing and treating inflammatory bowel disease
CA3000569A1 (en) * 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
WO2017059225A1 (en) * 2015-09-30 2017-04-06 Celgene Corporation Tlr modulators and methods of use
EP3420082A4 (en) 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
US11619832B2 (en) 2018-03-08 2023-04-04 Coopervision International Limited Identification of contact lens wearers predisposed to contact lens discomfort
CN110082538B (zh) * 2019-04-19 2021-12-03 中山大学附属第六医院 CCR9+IL-17+Treg细胞在制备用于检测NEC的试剂盒中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159697A (en) * 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
RU2185627C2 (ru) * 2000-09-11 2002-07-20 Новосибирская государственная медицинская академия Способ определения чувствительности (восприимчивости) к внутривенной лазеротерапии больных ишемической болезнью сердца
EP1456380B1 (en) 2001-11-02 2012-04-18 Giuliani International Limited Smad7 inhibitors for the treatment of cns diseases
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US20090275496A1 (en) 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
EP1913387B1 (en) * 2005-08-02 2016-01-20 Centenary Institute of Cancer Medicine & Cell Biology Method for identifying regulatory t cells
EP2122018A4 (en) * 2006-03-10 2010-04-07 Mount Sinai Hospital Corp DIAGNOSTIC COMPOSITIONS AND TREATMENT METHODS FOR SUFFERING WITH TROPHOBLAST CELL DEOD, DIFFERENTIATION, INVASION, AND / OR CELL FUSION AND TURNOVER
EP2167647A2 (en) * 2007-06-13 2010-03-31 La Jolla Institute For Allergy And Immunology Regulatory t cells and methods of making and using same
CN101960021A (zh) * 2008-02-28 2011-01-26 希森美康株式会社 产生il-17的辅助t细胞检测用标记及产生il-17的辅助t细胞的检测方法
JP2010051307A (ja) 2008-07-28 2010-03-11 Eisai R & D Management Co Ltd Ｔｈ１７細胞およびＴｒｅｇ細胞の分化誘導を調節する物質のスクリーニング方法
RU2593939C2 (ru) 2008-11-13 2016-08-10 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
CN102483405B (zh) 2009-07-10 2015-12-02 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
AU2014229985B2 (en) 2013-03-15 2018-12-13 Nogra Pharma Limited Methods of treating colorectal cancer
AU2015257589A1 (en) 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
EP3207136A1 (en) 2014-10-17 2017-08-23 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3213070A2 (en) 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
CA3000569A1 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression

Similar Documents

Publication Publication Date Title
JP2014531584A5 (https=)
RU2014114838A (ru) Способы контроля восприимчивости анти-smad7 терапии
JP6941324B2 (ja) 新規な肝硬変または肝線維症のマーカー
Singh et al. First mass screening of the human population to estimate the bio-load of Mycobacterium avium sub-species paratuberculosis in North India
JP7008739B2 (ja) 細胞媒介免疫応答アッセイ
CN111778341B (zh) 一种活动性肺结核的生物标志物及其应用
Singh et al. Inflammatory chemokines and their receptors in human visceral leishmaniasis: Gene expression profile in peripheral blood, splenic cellular sources and their impact on trafficking of inflammatory cells
Golby et al. MicroRNA expression profiling of PPD-B stimulated PBMC from M. bovis-challenged unvaccinated and BCG vaccinated cattle
CN112608995B (zh) 一种肺结核病特异性标志物及应用和试剂盒
Masala et al. Role of Chlamydophila abortus in ovine and caprine abortion in Sardinia, Italy
Hewitt et al. A prime-boost concept using a T-cell epitope-driven DNA vaccine followed by a whole virus vaccine effectively protected pigs in the pandemic H1N1 pig challenge model
CN118979104A (zh) 脓毒症相关疾病早期诊断标志物及其用途
CN108845129A (zh) 一种活动性结核类疾病的生物标志物的应用
Hao et al. Hepatitis B virus upregulates the expression of C-reactive protein both in vivo and in vitro
Stepanova et al. Different immune response of pigs to Mycobacterium avium subsp. avium and Mycobacterium avium subsp. hominissuis infection
CN107267659B (zh) 检测trim基因和/或蛋白水平的产品的用途
CN107653308B (zh) 一组用于区分活动性结核病人与非结核性肺炎病人的引物对组合及试剂盒
Veld et al. An IL-10 homologue encoded by human cytomegalovirus is linked with the viral “footprint” in clinical samples
Nouailles et al. Longitudinal omics in Syrian hamsters integrated with human data unravel complexity of moderate immune responses to SARS-CoV-2
CN106520916B (zh) lncRNA-MIR3945HG V2在菌阴肺结核诊断中的应用
CN110527721A (zh) 一种陈旧性结核病标志物及其应用
Jiménez et al. Expression of non-replicating persistence associated genes of Mycobacterium bovis in lymph nodes from skin test-reactor cattle
WO2016176789A1 (es) Biomarcadores para predecir respuesta a un tratamiento inmunomodulador en pacientes con enfermedad inflamatoria
CN113755614A (zh) 布鲁氏菌病疫苗株与野毒株快速高灵敏鉴别诊断试剂盒及其使用方法
WO2022051816A1 (en) Methods of determining immune response